Barclays
GBT

Barclays’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Barclays’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40,000
Closed -$1.73M – 5342
2020
Q4 		$1.73M Buy
+40,000
New +$1.97M ﹤0.01% 2350
2020
Q2 		– Sell
-900
Closed -$46K – 6441
2020
Q1 		$46K Sell
900
-400
-31% -$26.8K ﹤0.01% 5282
2019
Q4 		$103K Buy
1,300
+100
+8% +$5.93K ﹤0.01% 5467
2019
Q3 		$58K Sell
1,200
-5,000
-81% -$261K ﹤0.01% 5843
2019
Q2 		$326K Buy
6,200
+5,000
+417% +$287K ﹤0.01% 4704
2019
Q1 		$64K Sell
1,200
-4,000
-77% -$197K ﹤0.01% 5700
2018
Q4 		$213K Sell
5,200
-73,200
-93% -$2.74M ﹤0.01% 4531
2018
Q3 		$2.98M Sell
78,400
-15,300
-16% -$678K ﹤0.01% 2417
2018
Q2 		$4.24M Buy
93,700
+93,500
+46,750% +$4.26M ﹤0.01% 1856
2018
Q1 		$10K Sell
200
-200
-50% -$11.2K ﹤0.01% 6666
2017
Q4 		$16K Buy
400
+200
+100% +$7.47K ﹤0.01% 6390
2017
Q3 		$6K Sell
200
-5,100
-96% -$143K ﹤0.01% 6373
2017
Q2 		$145K Sell
5,300
-700
-12% -$20.8K ﹤0.01% 4633
2017
Q1 		$221K Buy
6,000
+5,000
+500% +$126K ﹤0.01% 4214
2016
Q4 		$14K Buy
+1,000
New +$17.6K ﹤0.01% 5786

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's GBT Position: Q4 2022 in Review

Barclays sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 130,434 shares — an estimated $8.88M sold.

Barclays first reported a position in GBT in Q3 2015 and held it in 27 quarters. The position peaked at $18.9M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Barclays reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 130,434 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.88M.
  • Barclays first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 27 quarters.
  • Barclays's Global Blood Therapeutics, Inc. position peaked at $18.9M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.